Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy

Clinical Cancer Research

Volumn 9, Issue 5, 2003, Pages 1673-1679

  Licitra, Edward J ^a   Vyas, Viral ^a   Nelson, Kathy ^a   Musanti, Rita ^a   Beers, Stephanie ^a   Thomas, Cecilia ^a   Poplin, Elizabeth ^a   Smith, Sharon ^a   Lin, Yong ^a   Schaaf, Larry J ^a   Aisner, Joseph ^a   Gounder, Murugesan ^a   Rajendra, Rajeev ^a   Saleem, Ahamed ^a   Toppmeyer, Deborah ^a   Rubin, Eric H ^a,b  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b CINJ   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CISPLATIN; DNA TOPOISOMERASE; ETOPOSIDE; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; FEMALE; HUMAN; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; NAUSEA; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SARCOMA; STOMACH CANCER; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CAMPTOTHECIN; CISPLATIN; COHORT STUDIES; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; ETOPOSIDE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS;

EID: 0038666413     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Liu, L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem., 58: 351-375, 1989.
2. Desai, S. D., Li, T. K., Rodriguez-Bauman, A., Rubin, E. H., and Liu, L. F. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res., 61: 5926-5932, 2001.
3. Mao, Y., Sun, M., Desai, S. D., and Liu, L. F. SUMO-1 conjugation to topoisomerase I: a possible repair response to topoisomerase-mediated DNA damage. Proc. Natl. Acad. Sci. USA, 97: 4046-4051, 2000.
4. Mao, Y., Desai, S. D., Ting, C. Y., Hwang, J., and Liu, L. F. 26 S proteasome-mediated degradation of topoisomerase II cleavable complexes. J. Biol. Chem., 276: 40652-40658, 2001.
5. Mao, Y., Desai, S. D., and Liu, L. F. SUMO-1 conjugation to human DNA topoisomerase II isozymes. J. Biol. Chem. 275: 26066-26073, 2000.
6. Rubin, E. H., Li, T., Duan, P., and Liu, L. F. Cellular resistance to topoisomerase poisons. In: W. N. Hait (ed.) Drug Resistance, pp. 243-260. Norwell, MA: Kluwer Academic Publishers, 1996.
7. Rubin, E., Wood, V., Bharti, A., Trites, D., Lynch, C., Hurwitz, S., Bartel, S., Levy, S., Rosowsky, A., Toppmeyer, D., and Kufe, D. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin. Cancer Res., 1: 269-276, 1995.
8. Gupta, E., Toppmeyer, D., Zamek, R., Much, J., Ibrahim, N., Goodin, S., Kane, M., Aisner, J., Li, X.-G., Haluska, P., Medina, M., Cornfield, A., Vyas, V., Natelson, E., Giovanella, B., Saleem, A., and Rubin, E. Clinical evaluation of sequential topoisomerase targeting in the treatment of advanced malignancy. Cancer Ther., 1: 292-301, 1998.
9. Whitacre, C. M., Zborowska, E., Gordon, N. H., Mackay, W., and Berger, N. A. Topotecan increases topoisomerase IIα levels and sensitivity to treatment with etoposide in a schedule-dependent process. Cancer Res., 57: 1425-1428, 1997.
10. Kaufmann, S. H. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res., 51: 1129-1136, 1991.
11. Saleem, A., Ibrahim, N., Patel, M., Li, X-G., Gupta, E., Mendoza, J., Pantazis, P., and Rubin, E. H. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning. Cancer Res., 57: 5100-5106, 1997.
12. Saltz, L. B., Spriggs, D., Schaaf, L. J., Schwartz, G. K., Ilson, D., Kemeny, N., Kanowitz, J., Steger, C., Eng, M., Albanese, P., Semple, D., Hanover, C. K., Elfring, G. L., Miller, L. L., and Kelsen, D. Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. J. Clin. Oncol., 16: 3858-3865, 1998.
13. Hande, K., Messenger, M., Wagner, J., Krozely, M., and Kaul, S. Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration. Clin. Cancer Res., 5: 2742-2747, 1999.
14. Miller, A. B., Hoogstraten, B., Staquet, M., and Winkler, A. Reporting results of cancer treatment. Cancer, 47: 207-214, 1981.
15. Gibaldi, M., and Perrier, D. Pharmacokinetics, Ed. 2. New York: Marcel Deklor, Inc, 1982.
16. Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta. N., Elfring, G. L., and Miller, L. L. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med., 343: 905-914, 2000.
17. Noda, K., Nishiwaki, Y., Kawahara, M., Negoro, S., Sugiura, T., Yokoyama, A., Fukuoka, M., Mori, K., Watanabe, K., Tamura, T., Yamamoto, S., and Saijo, N. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med., 346: 85-91, 2002.
18. Masuda, N., Fukuoka, M., Kudoh, S., Matsui, K., Kusunoki, Y., Takada, M., Nakagawa, K., Hirashima, T., Tsukada, H., Yana, T., Yoshikawa, A., Kubo, A., Matsuura, E., Nitta, T., Takifuji, N., Terakawa, K., and Negoro, S. Phase I and phamacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. J. Clin. Oncol., 12: 1833-1841, 1994.
19. Oshita, F., Noda. K., Nishiwaki, Y., Fujita, A., Kurita, Y., Nakabayashi, T., Tobise, K., Abe, S., Suzuki, S., Hayashi, I., Kawakami, Y., Matsuda, T., Tsuchiya, S., Takahashi, S., Tamura, T., and Saijo, N. Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer. J. Clin. Oncol., 15: 304-309, 1997.
20. Tolcher, A. W., O'Shaughnessy, J. A., Weiss, R. B., Zujewski, J., Myhand, R. C., Schneider, E., Hakim, F., Gress, R., Goldspiel, B., Noone, M. H., Brewster, L. R., Gossard, M. R., and Cowan, K. H. A Phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancy. Clin. Cancer Res., 3: 755-760, 1997.
21. Ando, M., Eguchi, K., Shinkai, T., Tamura, T., Ohe, Y., Yamamoto, N., Kurata, T., Kasai, T., Ohmatsu, H., Kubota, K., Sekine, I., Hojo, N., Matsumoto, T., Kodama, T., Kakinuma, R., Nishiwaki, Y., and Saijo, N. Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer. Br. J. Cancer., 76: 1494-1499, 1997.
22. Hammond, L. A., Eckardt, J. R., Ganapathi, R., Burris, H. A., Rodriguez, G. A., Eckhardt, S. G., Rothenberg, M. L., Weiss, G. R., Kuhn, J. G., Hodges, S., Von Hoff, D. D., and Rowinsky, E. K. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide. Clin. Cancer Res., 4: 1459-1467, 1998.
23. Seiden, M. V., Ng, S. W., Supko, J. G., Ryan, D. P., Clark, J. W., Lynch, T., Huang, K. C., Kwiatkowski, D., Skarin, A., and Eder, J. P., Jr. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors. Clin. Cancer Res., 8: 691-697, 2002.
24. Matsumoto, N., Nakano, S., Esaki, T., Tatsumoto, T., Fujishima, H., Baba, E., Nakamura, M., and Niho, Y. Sequence-dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line. Anticancer Res., 15: 405-410, 1995.
25. Eder, J. P., Chan, V., Wong, J., Wong, Y. W., Ara, G., Northey, D., Rizvi, N., and Teicher, B. A. Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo. Cancer Chemother. Pharmacol., 42: 327-335, 1998.
26. Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J., Vokes, E. E., and Ratain, M. J. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res., 54: 3723-3725, 1994.
27. Brangi, M., Litman, T., Ciotti, M., Nishiyama, K., Kohlhagen, G., Takimoto, C., Robey, R., Pommier, Y., Fojo, T., and Bates, S. E. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res., 59: 5938-5946, 1999.
28. Crump, M., Lipton, J., Hedley, D., Sutton, D., Shepherd, F., Minden, M., Stewart, K., Beare, S., and Eisenhauer, E. Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: A National Cancer Institute of Canada Clinical Trials Group Study. Leukemia, 13: 343-347, 1999.
29. Mainwaring, M. G., Rimsza, L. M., Chen, S. F., Gomez, S. P., Weeks, F. W., Reddy, V., Lynch, J., May, W. S., Kahn, S., Moreb, J., Leather, H., Braylan, R., Rowe, T. C., Fieniewicz, K. J., and Wingard, J. R. Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels. Leuk. Lymphoma, 43: 989-999, 2002.